Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals (MIRM) delivers innovative therapies for rare liver diseases through targeted IBAT inhibitor development. This page provides centralized access to official announcements, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and healthcare professionals will find timely updates on regulatory milestones, partnership agreements, and pipeline advancements. Our curated feed includes verified press releases about Maralixibat approvals, Volixibat trial progress, and corporate initiatives addressing conditions like progressive familial intrahepatic cholestasis.
Key updates cover FDA communications, research collaborations, and commercialization strategies for orphan drug therapies. All content is sourced directly from Mirum’s disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Mirum’s latest advancements in minimally absorbed liver disease treatments. Check regularly for critical updates impacting clinical development timelines and therapeutic availability.
Mirum Pharmaceuticals announced the presentation of new long-term data from LIVMARLI studies at the upcoming EASL Annual Congress in Milan, Italy (June 5-8, 2024). The data highlights sustained clinical benefits of LIVMARLI for Alagille syndrome (ALGS) over seven years and improvements in liver markers and growth for Progressive Familial Intrahepatic Cholestasis (PFIC) patients. Key presentations include:
- THU-094: Clinical benefits of Maralixibat for ALGS patients through 7 years (MERGE Study).
- THU-129: Maralixibat improves growth in PFIC patients (MARCH/MARCH-ON Trials).
- THU-158: Serum bile acid levels and liver health improvements in PFIC children after Maralixibat treatment (MARCH/MARCH-ON Trials).
Additionally, a Mirum-sponsored symposium will discuss the role of IBAT inhibitors in adult hepatology and unmet needs in primary sclerosing cholangitis (PSC).
Mirum Pharmaceuticals presented data on their oral solution, LIVMARLI (maralixibat), at the 56th ESPGHAN Annual Meeting in Milan. Seven abstracts highlighted LIVMARLI's efficacy in treating Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Key findings from the Phase 3 MARCH-ON PFIC study showed significant and sustained improvements in pruritus severity, serum bile acid levels, total bilirubin, and growth over two years. One-third of patients on LIVMARLI discontinued at least one antipruritic medication. These results underscore LIVMARLI's potential in improving liver health and reducing medication dependency in children with PFIC and ALGS.
Mirum Pharmaceuticals, Inc. announced the granting of inducement awards to new employees under the 2020 Inducement Plan. The grants consist of stock options and restricted stock units (RSUs) totaling 38,600 shares of common stock and 19,300 RSUs. The stock options have an exercise price of $24.76 per share, will vest over four years, and the RSUs will vest over three years. The awards were approved by the Compensation Committee of Mirum's Board of Directors as an inducement material for the new employees' employment.
Mirum Pharmaceuticals reported a strong first quarter in 2024, with total revenue of $69.2 million and on track to achieve full-year guidance of $310 to $320 million. The FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients was achieved in March. The company maintains a cash balance of $302.8 million as of March 31, 2024, and has important interim analyses scheduled for June 2024. Mirum's commercial business is performing well, with continued demand growth and net sales increase.
Mirum Pharmaceuticals, a biopharmaceutical company specializing in rare and orphan diseases, is set to present at the Citizens JMP Life Sciences Conference in New York on May 14th. Investors can access the webcast via Mirum's website.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced the publication of Phase 3 MARCH data in The Lancet, showcasing the benefits of LIVMARLI (maralixibat) in patients with PFIC. The study confirmed the efficacy and safety of LIVMARLI across a broad genetic range of PFIC types, with significant improvements observed in pruritus, serum bile acids, growth, and bilirubin levels.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will announce its first quarter 2024 financial results on May 8, 2024, followed by a conference call to discuss recent corporate progress. The call will be accessible via phone or webcast.
FAQ
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
What is the market cap of Mirum Pharmaceuticals (MIRM)?
